(Weber Shandwick Worldwide) The Aplastic Anemia & MDS International Foundation is pleased to inform patients that the US Food and Drug Administration has expanded the label for Vidaza (azacitidine) to include data from the AZA-001 trial, which found that Vidaza is the only agent that extends survival in MDS (myelodysplastic syndromes) patients.

Vidaza was also shown to delay progression to acute myelogenous leukemia in patients with MDS. Roughly 30 percent of patients diagnosed with MDS will progress to AML.